Atrial fibrillation
Conditions
Interventions
Sacubitril valsartan group:None
Valsartan group:None
Sponsors
Peking University Shenzhen Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Male or female aged >=35 and = 30s single-lead ECG recordings in the 2022 ESC guidelines for the diagnosis of atrial fibrillation]; 3. Meet the diagnostic criteria for heart failure with preserved ejection fraction recommended by the 2014 Chinese Heart Failure Diagnosis and Treatment Guidelines: (1) Have typical symptoms; (2) LVEF>=50%; (3) NT-proBNP increased; 4. New York Heart Association (NYHA) cardiac function class I-II patients; 5. Left atrial diameter (LAD)<=40mm, left ventricular end-diastolic diameter (LVEDD)<=55mm; 6. The patient signed the informed consent form and was approved by the hospital ethics committee.
Exclusion criteria
Exclusion criteria: 1. Patients with hyperthyroidism, severe liver and kidney insufficiency, pulmonary hypertension, and cancer; 2. Patients with valvular disease, dilated cardiomyopathy, severe left ventricular insufficiency, and other structural heart diseases; 3. The patient is pregnant or breastfeeding; 4. Patients with contraindications to anticoagulation and catheter ablation; 5. Patients with left atrial appendage thrombosis 6. Systolic blood pressure <90mmhg, and/or diastolic blood pressure <60mmhg; 7. The life expectancy of the patient does not exceed 2 years; 8. Patients did not complete the one-year follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NT-proBNP;Blood urea nitrogen;Serum creatinine;Glomerular filtration rate;Left Ventricular Ejection Fractions, LVEF;Left atrium diameter;Left ventricular end-diastolic diameter;Echocardiography; | — |
Countries
China
Contacts
Public ContactWang Guan
Peking University Shenzhen Hospital
Outcome results
None listed